Company Profile: 23andMe
Summary
23andMe is a personal genomics and biotechnology company that leverages machine learning technology to provide DNA analysis services. It also offers web-based interactive tools to individuals, helping them understand their own genetics information.
Scope
The report provides information and insights into 23andMe, including -
- Overview of the company and its product offering
- Detailed insight into its business operation, technology, revenue model, geographical presence and business model
- Information on partnerships, funding and awards it received
- Biography of top management.
Reasons to buy
- Gain insights into 23andMe's business operations.
- Gain insights into funding and partnerships.
- Gain understanding about its technology focus and success ......
|
$350 |
|
Company Profile: Fitbit, Inc.
Summary
Fitbit, Inc. (Fitbit) offers a range of connected health and fitness devices that monitors various health parameters like sleep duration, heart rate, BMI, calories burned, exercise routines, etc.
Scope
The report provides information and insights into Fitbit, Inc., including -
- Overview of the company and its product offering
- Detailed insight into its business operation, technology, revenue model, geographical presence and business model
- Information on partnerships, funding and awards it received
- Biography of top management.
Reasons to buy
- Gain insights into Fitbit business operations.
- Gain insights into funding and partnerships.
- Gain understanding about its technology focus and success factors.......
|
$350 |
|
The State of the Microbiome
Summary
GlobalData's "The State of the Microbiome", report provides an assessment of how the pharmaceutical industry perceives the state of the microbiome, including the challenges associated with developing, launching, and manufacturing microbiome therapeutics as well as where opportunity remains to invest in the microbiome space.
Scope
- Microbiome investment - determine level of activity and investment in the development of microbiome therapeutics by therapy area
- Identify the challenges associated with
- Developing microbiome therapeutics
- Launching microbiome therapeutics
- Manufacturing microbiome therapeutics.
Reasons to buy
- Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with devel......
|
$1495 |
|
Rheumatoid Arthritis: Epidemiology Forecast to 2027
Summary
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the body's immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life.
GlobalData epidemiologists used sources that provided the diagnosed incidence, diagnosed prevalence, and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06.
In 2......
|
$3995 |
|
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018
Summary
GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2018. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informati......
|
$1500 |
|
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China
Summary
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
|
$1995 |
|
Brucellosis Global Clinical Trials Review, H2, 2018
Summary
GlobalData's clinical trial report, "Brucellosis Global Clinical Trials Review, H2, 2018" provides an overview of Brucellosis clinical trials scenario. This report provides top line data relating to the clinical trials on Brucellosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
|
$2500 |
|
Childhood Epilepsy Global Clinical Trials Review, H2, 2018
Summary
GlobalData's clinical trial report, "Childhood Epilepsy Global Clinical Trials Review, H2, 2018" provides an overview of Childhood Epilepsy clinical trials scenario. This report provides top line data relating to the clinical trials on Childhood Epilepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
|
$2500 |
|
Caries Global Clinical Trials Review, H2, 2018
Summary
GlobalData's clinical trial report, "Caries Global Clinical Trials Review, H2, 2018" provides an overview of Caries clinical trials scenario. This report provides top line data relating to the clinical trials on Caries. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80......
|
$2500 |
|
Chordoma Global Clinical Trials Review, H2, 2018
Summary
GlobalData's clinical trial report, "Chordoma Global Clinical Trials Review, H2, 2018" provides an overview of Chordoma clinical trials scenario. This report provides top line data relating to the clinical trials on Chordoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated......
|
$2500 |
|
